X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Blautia Hydrogenotrophica
Therapeutic Area: Gastroenterology Product Name: Blautix
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2021
Details:
In Phase II trial, where Blautix demonstrated signals of clinical activity in both IBS-C and IBS-D, and a highly favorable safety and tolerability profile.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): IMP731
Therapeutic Area: Gastroenterology Product Name: GSK2831781
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Immutep
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 22, 2021
Details:
GSK, has stopped its Phase II trial of anti-LAG3 cell depleting monoclonal antibody, GSK2831781 (derived from Immutep’s IMP731 antibody), in patients with active ulcerative colitis. The trial was stopped based on the assessment of clinical data of planned interim analysis.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Blautia Hydrogenotrophica
Therapeutic Area: Gastroenterology Product Name: Blautix
Highest Development Status: Phase II Product Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 07, 2020
Details:
The phase II trial showed that Blautix treatment resulted in: A statistically significant increase in overall response in pre-planned analysis of the combined IBS-C/D group compared to placebo; A positive, increase in overall response in both IBS-C and IBS-D cohorts.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
